Comprehensive M&A data with integrated detailed company information

BioNTech may go public in the near future: Bloomberg
Posted on Wednesday, 06 February 2019 13:52
BioNTech, which recently announced plans to purchase the antibody generation unit of MAB Discovery, is said to be considering an initial public offering (IPO) that could value the German cancer-vaccine manufacturer at over USD 5.00 billion, Bloomberg reported.

Citing people familiar with the matter, the news provider observed that the company is looking at the US as a potential marketplace to sell its shares, the amount, or price of which was not disclosed at this time.

BioNTech received an EUR 80.00 million investment from Sanofi at the start of this year, 12-months after it completed a funding round involving Janus Henderson, Invus Group and Fidelity Management & Research, worth USD 270.00 million.

The business has already approached advisors about a stock market flotation that could take place before the end of 2019, the sources told Bloomberg.

According to these insiders, plans are at an early stage and the ultimate value of BioNTech depends on investor demand.

Currently, no final decision has been made and the biotechnology group could decide to remain private, or, seek pre-financing first.

When contacted by Bloomberg, a spokeswoman for BioNTech said the company continues to consider and evaluate all potential options, including an IPO at “sometime in the future”.

Whether such plans are near, or far away, is still to be determined and would come on the back of a significant 12-month period for flotations in the pharmaceutical market.

Zephyr, the M&A database published by Bureau van Dijk, shows there were 70 IPOs of medicine manufacturers announced, or completed, worldwide last year, worth an aggregate USD 4.34 billion.

In terms of value this represents an improvement on the USD 2.56 billion-worth of deals signed off in 2017; however, it is not quite as high as the USD 7.13 billion recorded in 2016.

Elanco Animal Health, a US-based animal pharmaceutical products manufacturer, raised USD 1.45 billion in the largest of these last year.

© Zephus Ltd